Intimation of notice of 22nd AGM of Goldline Pharmaceutical Limited.

To Date: 06/08/2026 The Manager Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 544759, Scrip ID: GLPL, Sub: Intimation of Notice of 22nd Annual General Meeting of Goldline Pharmaceutical Limited. Sir / Ma’am, We wish to inform the Exchange that the 22nd Annual General Meeting (AGM) of Goldline Pharmaceutical Limited will be held on Saturday, 29th August, 2026 at 4:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025. The copy of Notice of 22nd Annual General Meeting (AGM) of the company is enclosed herewith. The same is for your information and record. Thanking you, Yours faithfully, FOR GOLDLINE PHARMACEUTICAL LIMITED Ruchi Sanket Modi Company Secretary cum Compliance Officer NOTICE Notice is hereby given that the 22nd Annual General Meeting of the members of Goldline Pharmaceutical Limited (CIN: L51397MH2004PLC147806) will be held on Saturday, 29th August, 2026 at 4:00 P.M at the Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025 to consider the following business: ORDINARY BUSINESS: ITEM NO. 01 - Adoption of Audited Financial Statements To receive, consider and adopt the Standalone Audited Balance Sheet for the year ended 31st March, 2026, the Profit and Loss account for the year ended as on the said date, Cash Flow Statement, Auditors' Report and the Directors' Report thereon. ITEM NO. 02 - Declaration of Dividend on Preference Shares To declare dividend on preference shares for the financial year 2025-26. ITEM NO. 03 - Re-appointment of a Director To re-appoint Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686) who retires by rotation and being eligible, offers himself for the re- appointment. To consider and, if thought fit, to pass the following resolution, with or without modification as an Ordinary Resolution: “RESOLVED THAT Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686), who retires by rotation in terms of Section 152 of Companies Act, 2013 and being eligible be and is hereby re- appointed as Executive Director of the Company whose office shall be liable to retirement by rotation. SPECIAL BUSINESS: ITEM NO. 04 - To approve existing as well as new material related party transactions with Activista Healthcare Private Limited: To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended, the applicable provisions of the Companies Act, 2013 (“the Act”) read with the rules framed thereunder, other applicable laws including any amendments, modifications or re- enactments thereof from time to time, the Company’s Policy on Related Party Transactions, and subject to such approvals, consents, and permissions as may be required, the approval of the shareholders of the Company be and is hereby accorded to enter into and/or continue with existing and new material related party transaction(s), contract(s), arrangement(s) or agreement(s), whether entered individually or in aggregate or as part of a series, with Activista Healthcare Private Limited, Indore, is a Enterprises over which relatives of KMP are able to exercise significant influence and a related party as per Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, during the financial year ending March 31, 2026, on such material terms and conditions as specified in the Explanatory Statement to this resolution and as may be mutually agreed upon by the Company and the related party, provided that such transactions shall be undertaken in the ordinary course of business and on an arm’s length basis. RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include the Audit Committee and/or any other Committee duly constituted or to be constituted by the Board), be and is hereby authorised to do all such acts, deeds, matters, and things as may be necessary, desirable or expedient to give effect to this resolution including finalising and executing agreements, documents, applications and other writings, seeking approvals as may be required, and to delegate all or any of its powers herein conferred to any Committee or any director(s) or officer(s) of the Company as it may in its absolute discretion deem fit, without seeking any further approval of the shareholders.” RESOLVED FURTHER THAT all actions taken or to be taken by the Board or any officer of the Company in connection with the transactions referred to in this resolution be and are hereby approved, confirmed and ratified in all respects.” ITEM NO. 05 - To approve existing as well as new material related party transactions with Nucleage Pharma Solutions Private Limited: To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended, the applicable provisions of the Companies Act, 2013 (“the Act”) read with the rules framed thereunder, other applicable laws including any amendments, modifications or re- enactments thereof from time to time, the Company’s Policy on Related Party Transactions, and subject to such approvals, consents, and permissions as may be required, the approval of the shareholders of the Company be and is hereby accorded to enter into and/or continue with existing and new material related party transaction(s), contract(s), arrangement(s) or agreement(s), whether entered individually or in aggregate or as part of a series, with Nucleage Pharma Solutions Private Limited, Indore, is a Enterprises over which relatives of KMP are able to exercise significant influence and a related party as per Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, during the financial year ending March 31, 2026, on such material terms and conditions as specified in the Explanatory Statement to this resolution and as may be mutually agreed upon by the Company and the related party, provided that such transactions shall be undertaken in the ordinary course of business and on an arm’s length basis. RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include the Audit Committee and/or any other Committee duly constituted or to be constituted by the Board), be and is hereby authorised to do all such acts, deeds, matters, and things as may be necessary, desirable or expedient to give effect to this resolution including finalising and executing agreements, documents, applications and other writings, seeking approvals as may be required, and to delegate all or any of its powers herein conferred to any Committee or any director(s) or officer(s) of the Company as it may in its absolute discretion deem fit, without seeking any further approval of the shareholders.” RESOLVED FURTHER THAT all actions taken or to be taken by the Board or any officer of the Company in connection with the transactions referred to in this resolution be and are hereby approved, confirmed and ratified in all respects.” ITEM NO. 06 - To approve existing as well as new material related party transactions with Numerius Healthcare Private Limited: To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended, the applicable provisions of th [Showing first 8,000 characters — download PDF for full document]